CD274 and neoplasm: Tumor-specific major histocompatibility complex-II (tsMHC-II) has been identified as a potential biomarker for PD-1/PD-L1 targeted immunotherapy in other cancer types including melanoma6,7, Hodgkin lymphoma8 and bladder cancer9.